Cargando…
Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA‐REG OUTCOME trial
AIM: To investigate the association of the Thrombolysis In Myocardial Infarction (TIMI) Risk Score for Heart Failure in Diabetes (TRS‐HF(DM)) with mortality using data from the EMPA‐REG OUTCOME trial. MATERIALS AND METHODS: In EMPA‐REG OUTCOME, patients with type 2 diabetes and atherosclerotic cardi...
Autores principales: | Verma, Subodh, Sharma, Abhinav, Zinman, Bernard, Ofstad, Anne Pernille, Fitchett, David, Brueckmann, Martina, Wanner, Christoph, Zwiener, Isabella, George, Jyothis T., Inzucchi, Silvio E., Butler, Javed, Mazer, C. David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318207/ https://www.ncbi.nlm.nih.gov/pubmed/32227432 http://dx.doi.org/10.1111/dom.14015 |
Ejemplares similares
-
Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME
por: Pellicori, Pierpaolo, et al.
Publicado: (2020) -
Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial
por: Fitchett, David, et al.
Publicado: (2021) -
Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial
por: Inzucchi, Silvio E, et al.
Publicado: (2020) -
Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial
por: Vaduganathan, Muthiah, et al.
Publicado: (2021) -
Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial
por: Verma, Subodh, et al.
Publicado: (2021)